高齢者ブレインバンク https://www2.tmig.or.jp/brainbk/
リソース研究_研究成果_2017 年
1. Akasaka-Manya K, Kawamura M, Tsumoto H, Saito Y, Kitazume S, Hatsuta H, Miura Y, Hisanaga S,Murayama S, Hashimoto Y, Manya H, Endo,T; Excess APP O-glycosylation by GalNAc-T6 decreases
Aβ production. J Biochem. 2017, 161 (1): 99-111.
2. Dzamko N, Gysbers AM, Bandopadhyay R, Bolliger MF, Uchino A, Zhao Y, Takao M, Wauters S, vande Berg, WD, Takahashi-Fujigasaki J, Nichols RJ, Holton JL, Murayama S, Halliday GM: LRRK2levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. MovDisord. 2017; 32(3): 423-432.
3. Hara N, Kikuchi M, Miyashita A, Hatsuta H, Saito Y, Kasuga K, Murayama S, Ikeuchi T, Kuwano R:
Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer'sdisease. Acta Neuropathol Commun. 2017; 31; 5 (1) :10.
4. Honma N, Saji S, Mikami T, Yoshimura N, Mori S, Saito Y, Murayama S, Harada N: Estrogen-Related
Factors in the Frontal Lobe of Alzheimer's Disease Patients and Importance of Body Mass Index. Sci
Rep. 2017; 7 (1): 726.
5. Morimoto S, Hatsuta H, Komiya T, Kanemaru K, Tokumaru A. M, Murayama S: Simultaneous
skin-nerve-muscle biopsy and abnormal mitochondrial inclusions in intranuclear hyaline inclusion
body disease. J Neurol Sci. 2017; 372: 447-449.
6. Morimoto S, Takao M, Hatsuta H, Nishina Y, Komiya T, Sengoku R, Nakano Y, Uchino A, Sumikura
H, Saito Y, Kanemaru K, Murayama S: Homovanillic acid and 5-hydroxyindole acetic acid asbiomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed
study. PLoS One 2017; 12 (2) : e0171524.

7. Kokubo Y, Banack S. A, Morimoto S, Murayama S, Togashi T, Metcalf J. S, Cox P. A, Kuzuhara
S: beta-N-methylamino-l-alanine analysis in the brains of patients with Kii ALS/PDC. Neurology
89(10): 1091-1092.
8. Sabbagh MN, Schauble B, Anand K, Richards D, Murayama S, Akatsu H, Takao M, Rowe CC,Masters CL, Barthel H, Gertz HJ, Peters O, Rasgon N, Jovalekic A, Sabri O, Schulz-Schaeffer WJ andSeibyl J; Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's
Disease. J Alzheimers Dis. 2017; 56(2): 441-446..
9. Sakurai K, Tokumaru AM, Shimoji K, Murayama S, Kanemaru K, Morimoto S, Aiba I, Nakagawa M,Ozawa Y, Shimohira M, Matsukawa N, Hashizume Y and Shibamoto Y: Beyond the midbrain atrophy:
wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclearpalsy. Neuroradiology. 2017; 59(5): 431-443.
10. Yamamoto T, Murayama S, Takao M, Isa T, Higo N : Expression of secreted phosphoprotein 1(osteopontin) in human sensorimotor cortex and spinal cord: Changes in patients with amyotrophic
lateral sclerosis. Brain Res; 2017; 1655: 168-175.
11. Kobayashi M, Sumiyama K, Shimojima N, Shimojima N, Ieiri S, Okano H, Kamba S, Fujimura T,Hirobe S, Kuroda T, Takahashi-Fujigasaki J : Technical Feasibility of Visualizing Myenteric Plexus
Using Confocal Laser Endomicroscopy. J Gastroenterol Hepatol. 2017 Sep;32(9):1604-10112. Nakano Y, Takahashi-Fujigasaki J, Sengoku R, Kanemaru K, Arai T, Kanda T, Murayama S. PML
Nuclear Bodies Are Altered in Adult-Onset Neuronal Intranuclear Hyaline Inclusion Disease. J
Neuropathol Exp Neurol. 2017 Jul 1;76(7):585-594.

13. Araki W, Hattori K, Kanemaru K, Yokoi Y, Omachi Y, Takano H, Sakata M, Yoshida S, Tsukamoto T,
Murata M, Saito Y, Kunugi H, Goto Y, Nagaoka U, Nagao M, Komori T, Arima K, Ishii K, Murayama,S. Matsuda H, Tachimori H, Araki YM, Mizusawa H: Re-evaluation of soluble APP-alpha andAPP-beta in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders.
Biomark Res. 2017. 5: 28.
14. Kimura H, Takao M, Suzuki N, Kanemaru K, Mihara B, Murayama S: Pathologic Study ofIntracranial Large Artery Atherosclerosis in 7260 Autopsy Cases. J Stroke Cerebrovasc Dis.
2017: ;26(12):2821-2827.
15. Kakuda N, Miyasaka T, Iwasaki N, Takashi Nirasawa T, Satoko Wada-Kakuda S,Takahashi-Fujigasaki J, Murayama S, Ihara Y, Ikegawa M. Distinct deposition of amyloid-β species
in brains with Alzheimer's disease pathology visualized with MALDI imaging mass spectrometry.
Acta Neuropathologica Communications.2017;5:73
16. Mano T, Nagata K, Nonaka T, Tarutani A, Imamura T, Hashimoto T, Bannai T, Koshi-Mano K,Tsuchida T, Ohtomo R, Takahashi-Fujigasaki J, Yamashita S, Ohyagi Y, Yamazaki R, Tsuji S,Tamaoka A, Ikeuchi T, Saido CT, Iwatsubo T, Ushijima T, Murayama S, Hasegawa M, Iwata A:
Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of
BRCA1 in Alzheimer’s disease. PNAS.2017;114(45) : E9645-E9654

2